The global Real World Evidence (RWE) Solutions Market is projected to grow substantially, from USD 43.22 billion in 2022 to USD 78.83 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 7.8%. ⁤⁤This growth is driven by the rising adoption of RWE solutions in healthcare, which includes data from electronic health records, claims databases, and wearable devices to enhance clinical practice and decision-making. ⁤⁤The demand for RWE solutions is fueled by the need for evidence-based decision-making, regulatory requirements, and value demonstration across the healthcare and pharmaceutic ..read more

⁤Verantos, a leader in real-world evidence, has launched their Inflammatory Bowel Disease (IBD) Pragmatic Registry, which offers in-depth data on patients with ulcerative colitis and Crohn’s disease. ⁤⁤This registry integrates both unstructured and structured data from electronic health records, claims, and mortality data, providing a comprehensive view of disease severity, treatment effectiveness, symptom management, and medical resource use. ⁤⁤Through the use of AI, the registry provides deep phenotyping, allowing the creation of specific subgroups and trial-similar cohorts while enhancing ..read more

Eleos, founded by Dror Zaide, uses innovative technology to streamline documentation for behavioral health providers, shortening the documentation process by 50%. In an interview with Behavioral Health Business, Zaide, a former Israeli Air Force drone pilot with personal connections to mental health challenges, details how this technology will provide clinicians more time to focus more on patient care. Eleos addresses major healthcare issues such as care quality and staffing shortages by enhancing efficiency and compliance in documentation. The platform quickly generates clinically compliant ..read more

⁤Parexel, a leading clinical research organization, has partnered with Palantir Technologies with the intent of using AI to improve clinical trials for biopharmaceutical clients. ⁤⁤Parexel will integrate Palantir’s Foundry and AI Platform into its clinical data system to enhance trial efficiency while maintaining safety and regulatory standards. ⁤⁤This move expands their previous collaboration and marks Parexel as the first CRO to use Palantir’s AI tools in this capacity. ⁤⁤Jonathan Shough, Parexel’s CIO, emphasized the benefits of AI to optimize clinical trial execution and develop new solu ..read more

⁤Commons Clinic is helping reshape orthopedic healthcare by investing $9.75M in Marina Orthopedic & Spine Institute (MOSI) and launching Theater, a technology platform. ⁤⁤This investment further expands Commons Clinic’s network of Ambulatory Surgery Centers (ASCs), aligning with a trend towards outpatient procedures that is expected to comprise 85% of all healthcare activities by 2028. ⁤⁤MOSI is known for its cost-effective, successful surgeries led by top spine specialists. ⁤⁤Theater revolutionizes MSK care by integrating modern technology for operational efficiency, specialized operati ..read more

⁤A recent publication from Cuba et al. ⁤⁤highlights the AMBORA trial, which demonstrated how common medication errors are in cancer patients receiving oral antitumor therapies, and how these errors can be reduced with focused clinical pharmacological/pharmaceutical care programs. ⁤⁤This trial compared the frequency and nature of these errors in two settings: a randomized controlled trial (RCT) and real-world clinical practice, specifically at the AMBORA Competence and Consultation Center of the Comprehensive Cancer Center Erlangen-EMN. ⁤⁤The analysis showed that medication errors were twice ..read more

⁤The European Commission has initiated an investigation into China’s public procurement practices for medical devices, increasing trade tensions ahead of President Xi Jinping’s visit to Europe. ⁤⁤This investigation, the first under the EU International Procurement Instrument (IPI), seeks to determine if European suppliers are being fairly treated in the Chinese market. ⁤⁤This could lead to restrictions on Chinese companies in EU public tenders if found unfair. ⁤⁤The investigation launched by the European Commission reflects a broader EU strategy to ensure reciprocity and open markets, echoin ..read more

In 2024, medical affairs teams are pivotal in driving strategic impact within the pharmaceutical industry. They navigate challenges in organizational transformation, artificial intelligence (AI) integration, and omnichannel engagement. Transforming organizational structures involves alignment with broader goals and excelling in scientific engagement. AI offers potential to streamline these processes and enhance decision-making, ultimately requiring a balanced implementation to supplement human expertise. Omnichannel strategies engage healthcare professionals across multiple platforms, shifti ..read more

Chiesi Global Rare Diseases has published survey results in the Orphanet Journal of Rare Diseases that underscore the persistent awareness gap and unique struggles of rare disease patients, specifically those with Fabry disease. Giacomo Chiesi emphasizes the importance of understanding the disease from a patient’s viewpoint to enhance healthcare delivery. The survey, involving 280 adult patients mainly from the U.S. and Canada, aimed to shed light on their daily challenges, disease monitoring patterns, and treatment impacts on quality of life. The findings revealed common symptoms like fatig ..read more

⁤The World Health Organization (WHO) has recently announced a revision of its classification of airborne pathogens, including SARS-CoV-2, after criticism of delayed recognition during the pandemic. ⁤⁤The WHO’s technical report replaces the previous three categories of viral transmission airborne, droplet, and aerosol, with “infectious respiratory particles”. ⁤⁤However, experts argue the term “through the air” is vague preferring “airborne” to describe transmission. ⁤⁤Despite debates, an overall agreement on the report’s importance for future pandemics was achieved amongst experts, as the ref ..read more